The estimated Net Worth of Puneet Mathur is at least $5.97 mil dollars as of 11 May 2021. Puneet Mathur owns over 2,739 units of Cronos Inc stock worth over $5,971 and over the last 4 years Puneet sold CRON stock worth over $0.
Puneet has made over 1 trades of the Cronos Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Puneet exercised 2,739 units of CRON stock worth $5,971 on 11 May 2021.
The largest trade Puneet's ever made was exercising 2,739 units of Cronos Inc stock on 11 May 2021 worth over $5,971. On average, Puneet trades about 913 units every 0 days since 2020. As of 11 May 2021 Puneet still owns at least 2,739 units of Cronos Inc stock.
You can see the complete history of Puneet Mathur stock trades at the bottom of the page.
Puneet's mailing address filed with the SEC is 111 PETER STREET, SUITE 300, , TORONTO, A6, M5V 2H1.
Over the last 4 years, insiders at Cronos Inc have traded over $30,495,757 worth of Cronos Inc stock and bought 1,848,320 units worth $4,899,192 . The most active insiders traders include Michael Ryan Gorenstein, Jason Marc Adler y Jeffrey David Jacobson. On average, Cronos Inc executives and independent directors trade stock every 15 days with the average trade being worth of $528,456. The most recent stock trade was executed by James Andrew Iii Mc Ginness on 29 August 2024, trading 14,618 units of CRON stock currently worth $31,867.
cronos group is a globally diversified and vertically integrated cannabis company with a presence across four continents. the company operates two wholly-owned canadian licensed producers regulated under health canada’s access to cannabis for medical purposes regulations: peace naturals project inc. (ontario), which was the first non-incumbent medical cannabis license granted by health canada, and original bc ltd. (british columbia), which is based in the okanagan valley. the company has multiple international production and distribution platforms: cronos israel and cronos australia. through an exclusive distribution agreement, cronos also has access to over 12,000 pharmacies in germany as the company focuses on building an international iconic brand portfolio and developing disruptive intellectual property.
Cronos Inc executives and other stock owners filed with the SEC include: